Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides “Quality Affordable Healthcare Products®” across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China.

Company Growth (employees)
Type
Public
HQ
Dublin, IE
Founded
1887
Size (employees)
13,300 (est)
Perrigo was founded in 1887 and is headquartered in Dublin, IE

Perrigo Office Locations

Perrigo has offices in Dublin and Allegan
Dublin, IE (HQ)
2 Lower Grand Canal St
Allegan, US
515 Eastern Ave

Perrigo Data and Metrics

Perrigo Financial Metrics

Perrigo's revenue was reported to be $1.2 b in Q1, 2017
USD

Revenue (Q1, 2017)

1.2 b

Gross profit (Q1, 2017)

464.4 m

Gross profit margin (Q1, 2017), %

39%

Net income (Q1, 2017)

71.6 m

EBIT (Q1, 2017)

128.5 m

Market capitalization (25-Jul-2017)

10.9 b

Closing share price (25-Jul-2017)

76.4

Cash (01-Apr-2017)

3.1 b
Perrigo's current market capitalization is $10.9 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

4.1 b4.6 b1.3 b

Revenue growth, %

13%(71%)

Cost of goods sold

2.9 b

Gross profit

1.7 b

Gross profit Margin, %

37%

EBIT

747.7 m

EBIT margin, %

16%

Net Income

(205.3 m)128 m(1.4 b)
USDQ3, 2014Q1, 2014Q2, 2014Q3, 2015Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.3 b1.4 b1.5 b1.4 b1.2 b

Cost of goods sold

795.9 m860.3 m913.8 m848.6 m729.6 m

Gross profit

548.8 m522.9 m567.2 m506.3 m464.4 m

Gross profit Margin, %

41%38%38%37%39%

R&D expense

41.6 m45.3 m47 m50.2 m39.8 m

Operating expense total

41.6 m45.3 m47 m50.2 m39.8 m

EBIT

188.6 m(303.8 m)238.3 m(1.5 b)128.5 m

EBIT margin, %

14%(22%)16%(112%)11%

Interest expense

43.4 m51.2 m57.4 m54.6 m53.3 m

Interest income

43.4 m

Pre tax profit

132.2 m(359.2 m)151.6 m(1.6 b)95.8 m

Income tax expense

19.6 m(24.6 m)(42.7 m)(316.3 m)24.2 m

Net Income

48.1 m96.3 m70.2 m(94.9 m)112.6 m(334.6 m)(140.3 m)(1.4 b)71.6 m
USDFY, 2014FY, 2015FY, 2016

Cash

799.5 m785.6 m622.3 m

Accounts Receivable

935.1 m1.3 b

Inventories

631.6 m838.9 m795 m

Current Assets

2.6 b3.2 b2.8 b

PP&E

932.4 m870.1 m

Total Assets

13.9 b19.7 b13.9 b

Accounts Payable

364.3 m747.5 m471.7 m

Current Liabilities

1.1 b1.7 b1.8 b

Non-Current Liabilities

4.1 b7.4 b6.1 b

Total Liabilities

5.2 b9.1 b7.9 b

Retained Earnings

1.9 b1.9 b(2.1 b)

Total Equity

8.7 b10.7 b6 b

Financial Leverage

1.6 x1.8 x2.3 x
USDQ3, 2014Q1, 2014Q2, 2014Q3, 2015Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

609.4 m891.5 m3.6 b506.5 m588.9 m641.8 m362.7 m3.1 b

Accounts Receivable

869.4 m924.7 m

Inventories

693.5 m656.8 m641.8 m637 m888 m868.8 m894.6 m884.6 m800.2 m

Current Assets

2.3 b2.6 b5.4 b5.1 b2.9 b3 b3 b2.6 b5.1 b

PP&E

761.7 m756.8 m769.2 m924.1 m896.3 m888.6 m881.3 m875.3 m

Total Assets

13.7 b13.8 b16.5 b16.2 b19.7 b19.7 b19.5 b17.5 b14 b

Accounts Payable

325.3 m309 m302.7 m323.2 m541.2 m559.9 m514.1 m507.9 m476.3 m

Current Liabilities

953 m1 b1.3 b1.3 b1.7 b2.1 b2.1 b1.5 b2.5 b

Non-Current Liabilities

4.2 b4 b5.4 b5.3 b7.3 b7.8 b7.5 b7.3 b5.4 b

Retained Earnings

1.8 b2 b2 b1.9 b2 b1.5 b1.7 b449 m(2 b)

Total Equity

8.6 b8.7 b9.7 b9.6 b10.7 b9.8 b(9.9 b)(8.7 b)6.1 b

Financial Leverage

1.6 x1.6 x1.7 x1.7 x1.8 x2 x-2 x-2 x2.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(205.3 m)128 m42.5 m

Depreciation and Amortization

358.9 m548.8 m182.4 m

Accounts Receivable

(230 m)(82 m)52.5 m

Inventories

83 m10.7 m(29.6 m)

Accounts Payable

(24.9 m)140.6 m(194.1 m)

Cash From Operating Activities

693.5 m1.2 b

Purchases of PP&E

(171.6 m)(137 m)(77.8 m)

Long-term Borrowings

(2 b)(1.8 b)(28.3 m)

Interest Paid

98.4 m143.2 m84.2 m

Income Taxes Paid

93.2 m131 m87.8 m
USDQ3, 2014Q1, 2014Q2, 2014Q3, 2015Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

48.1 m96.3 m70.2 m(94.9 m)112.6 m(334.6 m)(140.3 m)(1.4 b)71.6 m

Depreciation and Amortization

175.4 m182.5 m369.3 m556.3 m109.4 m

Accounts Receivable

46.2 m23 m42.3 m113.6 m50.1 m

Inventories

(57 m)(14.8 m)(50.3 m)(29.9 m)500 k

Accounts Payable

(194 m)300 k(41.1 m)(51.8 m)2.5 m

Purchases of PP&E

(38.6 m)(34.7 m)(57.1 m)(84.6 m)(22 m)

Long-term Borrowings

(14.3 m)(14.3 m)(28.7 m)(545.8 m)(13.6 m)

Interest Paid

6.2 m11.9 m89.5 m124.1 m

Income Taxes Paid

19.8 m34.5 m38 m116.6 m
Y, 2017

Financial Leverage

2.3 x

Perrigo Market Value History

Perrigo Median Salaries

Source: 11 public H-1B filings from Perrigo

Traffic Overview of Perrigo

Perrigo Online and Social Media Presence

Perrigo News and Updates

Breakingviews: Hostile Takeover Battle Can Weaken a Company’s Defenses

Companies like Perrigo, AstraZeneca and DuPont have recently fought hostile bidders, leaving an opening for activist investors to force change.

Activist Investor Starboard Just Sent a Scathing Letter to Perrigo’s CEO

It's one of the most aggressive activist hedge funds.

Starboard Value, Taking Stake in Perrigo, Looks to Make Another Big Investment Pay

The hedge fund that prodded Yahoo into selling its core business has urged the American drug maker to take steps to bolster its sagging stock price.

Perrigo Company Life and Culture

You may also be interested in